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Strains of the murine coronavirus mouse hepatitis virus type 4 (MHV-4) which contained a mutation in the
E2 peplomer glycoprotein were obtained by selection for resistance to neutralization by monoclonal antibodies.
Characterization of six variants representing two independent epitopes on E2, E2B and E2C, by in vitro
neutralization and antibody-binding assays demonstrated that selection for an alteration in epitope E2B also
resulted in changes in epitope E2C and vice versa. We observed a mutation frequency of approximately 10-4.3
to 10-4.6, which is consistent with the expected occurrence of single point mutations. The variant virus strains
were attenuated with respect to neurovirulence when compared with wild-type MHV-4. Mice normally develop
encephalomyelitis and die after wild-type MHV-4 infection. Mice receiving 2- to 3-log-higher doses of the
variant strains survived and developed demyelinating disease. As the disease progressed, evidence of
remyelination and ongoing demyelination was observed up to 65 days after infection. Virus reisolated 15 days
after infection retained the variant phenotype. The data indicate that the E2 glycoprotein plays a central role
in determining the cellular tropism and virulence of MHV-4 in the mouse.
Murine hepatitis virus type 4 (MHV-4; JHM strain) (1) is a
neurotropic member of the Coronaviridae (for a review, see
reference 33). Infection of adult mice by MHV-4 usually
culminates in encephalomyelitis with over 95% mortality. In
the small fraction of mice which survive the initial infection
by wild-type virus, chronic white matter disease occurs
which is characterized by focal demyelinating lesions in the
brain and spinal cord with subsequent remyelination and
recurrent demyelination (15, 16). The development of
demyelinating lesions is thought to be a primary effect of
virus infection and destruction of the oligodendrocyte (16,
34), and virus has been shown in one instance to persist in
the infected brain for up to 1 year after infection (15).
Resistance to MHV-4 infection in certain mouse strains,
notably SJL/J, is controlled by a single autosomal recessive
gene on chromosome 7 (14). Resistance is expressed in vivo
and in vitro in both neurons and macrophages. In the latter
cell type cultured in vitro, it appears that virus is able to
establish a primary infection in a limited number of cells of
the resistant genotype but is unable to spread to adjacent
cells in the culture (13). Several groups have described
temperature-sensitive (ts) or spontaneously occurring plaque
morphology mutants of MHV-4 which are altered in their
pathogenicity; this is in marked contrast to the highly
neurovirulent wild-type MHV-4. Haspel et al. (11) isolated a
mutant referred to as ts8 which upon intracerebral (i.c.)
inoculation causes no demonstrable encephalitis but induces
extensive white matter lesions. Studies of this mutant dem-
onstrated primary destruction of oligodendroglia with little
evidence of inflammatory response or neuronal involvement.
Stohlman et al. (25) described similar disease induced by a
spontaneously arising plaque morphology mutant termed
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DS. In neither model is a specific genetic lesion in the mutant
virus associated with loss of neuropathogenicity.
MHV-4 contains three major structural polypeptides, a
nucleocapsid protein and two glycoproteins, El and E2 (12,
27, 32). By using monoclonal antibodies (MAbs) directed
against these MHV-4 polypeptides, Collins et al. (6) demon-
strated that only anti-E2 MAbs neutralize virus infectivity in
vitro and concluded that the viral structure bearing active
sites for viral attachment to host cells and for cell-to-cell
fusion is the 180-kilodalton E2 glycoprotein. Cleavage of E2
to two nonidentical 90-kilodalton subunits is required for
activation of the fusion potential (28). Talbot et al. (30, 31)
identified three neutralizing epitopes (E2A, E2B, and E2C)
and two nonneutralizing epitopes (E2D and E2E) on E2.
Passively transferred MAbs directed against epitopes E2A
and E2B protect mice from lethal challenge with MHV-4 (3).
In protected mice, MHV-4 infection is not blocked, but virus
grows to titers 20-fold lower than those in control, unpro-
tected mice. Less extensive neuronal involvement is ob-
served, and no spread to neurons in the spinal cord occurs.
Oligodendrocytes in the spinal cord are infected, and
demyelination is evident in the protected mice. Moreover,
the lesions in these mice are associated with mild to moder-
ate mononuclear infiltrates (3). These data show that MAbs
to specific determinants on the E2 glycoprotein are capable
of altering the tropism and course of MHV-4 infection from
fatal encephalitis to a demyelinating disease. To further
investigate the role of E2 in disease, we used MAbs to select
variant virus strains which resisted neutralization. The i.c.
infection of mice with these E2 variants resulted in the
development of primary demyelination, with encephalitis
occurring only at virus doses 2 to 3 orders of magnitude
higher than the fatal wild-type dose. These variants were
therefore attenuated with respect to their virulence in mice.
Data in this study indicate that the E2 glycoprotein plays a
pivotal role in determining the cellular tropism and virulence
of MHV-4 in the mouse central nervous system (CNS).
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MATERIALS AND METHODS
Virus and cell culture. MHV-4 (JHM strain) was originally
obtained from L. P. Weiner and is routinely propagated on
the DBT mouse astrocytoma cell line as described previ-
ously (3).
MAbs. MAbs used in this study were either generated in
this laboratory (6) or graciously provided by John Fleming of
the University of Southern California. The properties of all
the MAbs have been described previously (3, 6, 8, 31).
Selection of variant viruses. A volume of 0.5 ml containing
5 x 105 PFU of a stock of MHV-4 that was plaque purified
three times was incubated for 30 min at 37°C with a 1:20
dilution of ascites fluid containing either anti-E2 MAb
4B11.6 or anti-E2 MAb 5A13.5. The MAbs were previously
shown to have virus neutralization titers of 1:31,600 and
1:158,000, respectively, expressed as 50% plaque reduction
doses per ml (3, 31). Virus that escaped neutralization was
plated onto DBT cells and cultivated in the presence of MAb
(1:40 dilution of ascites fluid) in the overlay medium for 24 h,
at which time a few foci of cytopathic effect were observed.
Medium was removed, and virus was plaque purified. Picked
plaques were suspended in 0.2 ml of medium containing a
1:20 dilution of ascites fluid and incubated at 37°C for 1 h.
Virus that escaped round 2 of neutralization was plaque
purified twice more, and a working stock was prepared and
retested for resistance to neutralization. Three variant virus
stocks selected with each MAb were chosen for detailed
analysis.
LD50 test. Eight BALB/c Byj mice were inoculated i.c.
with the indicated dose of virus in a total volume of 50 pAl.
The number of mice surviving was recorded each day for 14
days, at which time the 50% lethal dose (LD50) was calcu-
lated by the method of Reed and Muench (22).
Virus neutralization. The ability of the variant viruses to
escape neutralization was quantitated by a plaque reduction
neutralization assay. Ascites fluid was diluted in minimal
essential medium as indicated above and mixed with an
equal volume (0.5 ml) of virus stock diluted to contain 200
PFU of MHV-4. The virus-MAb mixtures were incubated at
37°C for 30 min, divided in half, and plated in duplicate on
monolayers of DBT cells in 35-mm tissue culture wells. After
adsorption for 1 h, monolayers were overlaid with 0.5%
agarose in medium 199 supplemented with 10% fetal bovine
serum and incubated for a further 72 h in a 37°C CO2
incubator. Cells were then fixed by the addition of 2 ml of
25% Formalin in phosphate-buffered saline (PBS) for 4 to 18
h. Overlays were removed after fixation, and monolayers
were stained with 0.1% crystal violet. Plaques were counted,
and percent neutralization was calculated.
Histopathology. For histology, anesthetized mice were
sacrificed by perfusion via the left ventricle with cold PBS
followed by 2.5% glutaraldehyde in PBS. Spinal cords and
brains were removed and placed in 2.5% glutaraldehyde
overnight, after which the tissue samples were transferred to
PBS and stored at 4°C. Tissues were embedded in Epon and
stained with hematoxylin and eosin for histology or with
para-phenylenediamine for detection of myelin. For electron
microscopy, thin sections were stained with uranyl acetate
and lead citrate and examined with a Siemens 101 electron
microscope.
Cocultivation. Brains were removed aseptically and diced
into 2- to 3-mm fragments. Trypsin EDTA solution (20 ml;
GIBCO Laboratories) was added, and the suspension was
gently rotated for 15 min at 22°C. Large fragments of tissue
were allowed to settle at 1 x g, and the supernatant was
decanted. More trypsin EDTA solution (20 ml) was added,
and the digestion procedure was repeated. The supernatants
were pooled, and the cells were pelleted. The cell pellets
were suspended in 1 ml of minimal essential medium and
plated onto 80% confluent monolayers of DBT cells. Me-
dium was replaced after 48 h, and the cocultures were
screened daily for the appearance of syncytia. Virus was
recovered from the supernatant of frozen and thawed
cocultures by passage on DBT cells. In some instances early
in infection, virus was detected by plaque assay in 10%
(wt/vol) homogenates of brain and liver.
Antibody-binding assay. The binding of anti-E2 MAbs to
variant or wild-type MHV-4 was assayed by indirect immu-
nofluorescence on acetone-fixed infected cell monolayers.
MAb culture fluids were used undiluted, and staining was
developed by using fluorescein isothiocyanate-conjugated
sheep anti-mouse immunoglobulin G prepared in this labo-
ratory (4, 30).
RESULTS
Selection of MAb-resistant variants. A 5 x 105-PFU sample
(in 0.5 ml) of a stock of MHV-4 that had been plaque purified
three times was neutralized by incubation for 30 min at 37°C
with a 1:20 dilution of ascites fluid containing either MAb
5A13.5 or MAb 4B11.6. Approximately 0.01 to 0.1% of the
virus escaped neutralization, and of this resistant virus,
approximately 10% of the clones were bona fide MAb-
resistant variants (data not shown). Variants obtained in this
manner were assayed for resistance to neutralization by
MAbs directed against epitopes E2A, E2B, and E2C. A total
of 12 variants were selected by MAb 5A13.5, and 24 variants
were selected by MAb 4B11.6. Variants were selected by
these MAbs at mutation frequencies of 10-46 and 10-43,
respectively. Variants obtained by using MAb 5A13.5 were
designated V5A13.1, V5A13.2, V5A13.3, etc., those se-
lected with MAb 4B11.6 were designated V4B11.1,
V4B11.2, V4B11.3, etc.
Neutralization of variant and wild-type MHV-4 by MAbs.
The ability of MAbs 5B19.2 (E2A), 5A13.5 (E2B), and
4B11.6 (E2C) to neutralize wild-type MHV-4 or the variants
was determined. All three MAbs neutralized over 99% of
wild-type virus effectively at low dilutions (i.e., 1:100) and
had titers of 103 5(5B19.2), > 104 3 (5A13.5), and 104-2
(4B11.6) (Fig. 1). Variants V5A13.1, V5A13.2, and V5A13.3
resisted neutralization by MAb 5A13.5 (the selecting MAb)
and by MAb 4B11.6 but did not resist neutralization by MAb
5B19.2. In like manner, variants V4B11.1, V4B11.2, and
V4B11.3 resisted neutralization by both MAbs 5A13.5 and
4B11.6. Therefore, it appears that a mutation resulting in
acquisition of resistance to MAbs against epitope E2B also
confirmed resistance at epitope E2C and vice versa.
Binding of anti-E2 MAbs to the variant viruses. Resistance
to neutralization may result either from the failure ofMAb to
bind viral antigen or from the inability of the bound MAb to
induce structural perturbations or block functional sites
required for successful infection. To investigate these alter-
natives, we assessed the binding of 17 anti-E2 MAbs to
wild-type MHV-4, to the ts8 mutant (11), and to six MAb-
resistant variants. Representative results are shown in Fig. 2
and are summarized in Table 1. All 17 MAbs bound to both
wild-type MHV-4- and to ts8-infected cells. MAbs to
epitopes E2A, E2D, and E2E (30, 31) as well as several
MAbs from J. Fleming, which have not been assigned to any
of the epitopes described by Talbot et al. (31), also bound to
all the variant strains, indicating that the epitopes recognized
J. VIROL.
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FIG. 1. Neutralization of wild-type and MAb-selected variant strains of MHV-4 by anti-E2 MAbs. MAbs to epitopes E2A (5B19.2), E2B
(5A13.5), and E2C (4B111.6) were assayed over a 4-log range for the ability to neutralize wild-type MHV-4 (JHM) and the six variants V5A13.1,
V5A13.2, V5A13.3, V4B11.1, V4B11.2, and V4B11.3. All seven virus strains were effectively neutralized by MAb 5B19.2 (epitope E2A).
Variants V5A13.1, V5A13.2, and V5A13.3 were resistant to neutralization by MAbs 5A13.5 (epitope E2B, the selecting MAb) and 4B11.6
(epitope E2C). Similarly, variants V4B11.1, V4B11.2, and V4B11.3 resisted neutralization by both MAbs 5A13.5 and 4B11.6.
by these MAbs were intact on the variant E2 polypeptides.
MAbs 5A13.5 (epitope E2B) and 4B11.6 (epitope E2C) failed
to bind to any of the variants, confirming data obtained by
neutralization assay. Several unassigned MAbs also failed to
5B1 9.2
bind to variant E2 polypeptides. At least two of these, J.7.5
and J.7.6 (8) are thought to recognize structures different
from those recognized by MAbs 5A13.5 and 4B11.6 (30).
This result strongly suggests that the alteration in the variant
5A1 3.5 4B1 1.6
JHM
V5A-1 3.1
V4B-11.3 I
FIG. 2. Binding of anti-E2 MAbs to wild-type and MAb-selected variant strains of MHV-4. DBT cell monolayers infected with wild-type
MHV-4 (JHM) or the variants V5A13.1 or V4B11.3 were acetone fixed at 18 h postinfection. The ability of MAbs 5B19.2 (epitope E2A),
5A13.5 (epitope E2B), and 4B11.6 (epitope E2C) to bind to viral antigen was determined by indirect immunofluorescence. Bound MAb was
visualized by using fluorescein isothiocyanate-conjugated sheep anti-mouse immunoglobulin G. MAb 5B19.2 bound to wild-type MHV-4
(JHM) and both variants. MAbs 5A13.5 and 4B11.6 also bound to wild-type MHV-4 (JHM) but failed to bind to either variant.
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TABLE 1. Reactions of variant and wild-type MHV-4 strains with anti-E2 MAbs"
Virus strain
MAb Neutralization
V5A13.1 V5A13.2 V5A13.3 V4B11.1 V4B11.2 V4B11.3
5B19.2 + + + + + + +
5B170.3 + + + + + + +
5A13.5 + - - - - -
4B11.6 + - - - - -
5B21.5 - + + + + + +
5B93.7 - + + + + + +
5B207.3 - + + + + + +
5B216.8 - + + + + + +
J.1.2 - - + + + +
J.71.8 + - - - - -
J.2.2 + - - - - -
J.7.2 + - _ - _ _
J.2.5 - + + + ± ± +
J.2.6 + + + + + + +
J.7.1 - + + + + + +
J.7.5 + - - - - -
J.7.6 + - - - - -
a All 17 MAbs had strong positive reactions to both wild-type MHV-4- and ts8-infected cells. +, Strong positive reaction; +, weak positive reaction; -, no
reaction.
E2 polypeptides results in a conformation change(s) which
affects several distinct topographic sites on E2. The obser-
vation that MAb J.1.2 failed to bind to the variants we
selected, V5A13.1 and V4B11.3, yet did bind to the four
remaining variants suggests that these are distinct variant
strains. Neutralization of the variants we selected by MAb
J.1.2 was not tested.
Virulence of variant viruses. BALB/c Byj mice were inoc-
ulated i.c. with 50 and 1,000 PFU of each of the variant
viruses V5A13.1, V5A13.2, V5A13.3, V4B11.1, V4B11.2,
V4B11.3, or with wild-type MHV-4. Infected mice were
observed for 14 days, and mortality was recorded. After
inoculation with wild-type MHV-4, all the mice died by day
7. In contrast, inoculation with the variant strains resulted in
little mortality, indicating that the variants were attenuated
in neurovirulence. Following up these initial observations,
we selected variants V5A13.1 and V4B11.3 and determined
LD50 values for each (Fig. 3). Wild-type MHV-4 (JHM) had
an LD50 of less than 0.45 PFU, confirming the high virulence
of that virus. Variants were greatly reduced in pathogenicity
in this assay; V5A13.1 had an LD50 of >1,800 PFU, the
highest dose we could inoculate safely in 0.05 ml, and
V4B11.3 had an LD50 of 95 PFU. Thus, V5A13.1 was
attenuated by a factor of 4,000-fold or more, and V4B11.3
Variant V5A1 3.1 Variant V4B1 1.3
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FIG. 3. Attenuation of MAb-selected variants of MHV-4. Eight BALB/c Byj mice were i.c. inoculated with the indicated doses of
wild-type MHV-4 (JHM) or variants V5A13.1 and V4B11.3 in a total volume of 50 ,u. The number of mice surviving was recorded each day
for 14 days, at which time the LD50 was calculated by the method of Reed and Muench (22).
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FIG. 4. Focal area of demyelination next to an inflammatory infiltrate in the meninges. Resin-embedded tissue from the spinal cord of a
BALB/c mouse at 15 days postinfection. Magnification. x500.
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FIG. 5. Plaques of demyelination in the spinal cord of a mouse at 32 days postinfection. Magnification, x50.
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FIG. 6. Demyelina'tion and early remyelination (arrow) in a lesion from the spinal cord at 15 days postinfection. Magnification, x8,000.
was attenuated by approximately 200-fold relative to wild-
type virus.
Histopathological evidence of subclinical disease in variant
virus-infected mice. BALB/c Byj mice were inoculated i.c.
with 0.5 LD50 of V5A13.1 or V4B11.3 (900 and 50 PFU,
respectively), and groups of two mice were killed by cardiac
perfusion on days 4, 15, 22, 32, 50, and 65 postinfection. At
4, 15, and 22 days, moderate mononuclear infiltration was
observed in the spinal cord with inflammatory cells penetrat-
ing into the white matter (Fig. 4). Para-phenylenediamine-
stained plastic-embedded sections of spinal cord taken 15,
22, 32, 50, and 65 days postinfection showed plaques of
demyelination as well as areas of remyelination (Fig. 5 and
6). Examination of these lesions by electron microscopy
revealed naked axons. Thin myelin sheaths (Fig. 6), indica-
tive of a remyelinating repair process, were evident as early
as 15 days postinfection and persisted for the duration of the
study.
Isolation of virus from infected brains by cocultivation.
Brains were aseptically removed from one mock-, two
V5A13.1- and two V4B11.3-infected mice at days 15, 32, 50,
and 65, and virus was cocultivated on DBT cells as described
above. We were able to recover and subculture virus at day
15 from a V4B11.3-infected mouse, but attempts at
cocultivation of virus from VSA13.1-infected mice were
negative. The virus recovered from a V4B11.3-infected
mnouse was found to be resistant to neutralization by both
MAbs 4B11.6 and 5A13.5. Infectious virus was isolated
directly from brain and liver homogenates at 4 days postin-
fection, verifying that virus had infected these mice and had
spread to non-CNS sites of replication. A summary of the
virus titers in brains and livers at various times postinfection
is presented in Table 2.
DISCUSSION
Viral etiology of CNS demyelinating diseases is well
established in several animal models, including MHV-4 (15,
16), Theiler's virus (18), and visna virus infections (19).
Similarities of pathologic features between these experimen-
tally induced diseases and human disease as well as epide-
miologic observations suggesting infectious etiology (5) have
led investigators to propose a viral etiology for human
multiple sclerosis (35). Factors which affect the course of
CNS infections and ultimately determine whether an infec-
tion will be acute and self-limited, lethal, or chronic and
degenerative are poorly understood. Thus, studies of exper-
imental models such as MHV-4 are likely to yield new
insight. In the present report, we focused on molecular
determinants of MHV-4 neurotropism. We present evidence
indicating that mutations in the MHV-4 E2 peplomer glyco-
protein reflected by acquisition of resistance to neutralizing
MAbs resulted in attenuation of neurovirulence. Mice which
would normally die following wild-type MHV-4 infection
survived infection after receiving doses of the MAb-resistant
variant viruses 2 to 3 log higher than the wild-type dose, This
report and a similar study by J. Fleming and colleagues (9)
represent the first direct demonstrations of involvement of
the E2 glycoprotein in determination of MHV-4
neurovirulence.
The i.c. inoculation of susceptible mice with wild-type
MHV-4 (JHM) normally results in encephalomyelitis and
death within 7 days. Underlying the fatal disease is a primary
demyelinating condition which is observed in the small
percentage of animals which survive the infection or are
spared by passive transfer of protective antibody (3).
It was suggested by previous studies that the E2 peplomer
J. VIROL.
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TABLE 2. Virus content in brain and liver at various times after MHV-4 infection"
Virus strain
Day V4B-11.3 V5A-13.1 Wild-type MHV-4 (JHM)"
(mouse no.)
Brain Liver Brain Liver Brain Liver
1 2.5x103 <40 3.3x104 <40 5x104 5x 10
2 2.5 x 103 '.0 x 102 3.0 x 104 4.0 x 102
4
1 3.5 x 104 <40 2.5x 104 1.0 x 105 1 x 10" 1 x 104
2 3.0 x 103 <40 4.0 x 103 <40
7
1 <40 <40 <40 <40 4 x 1(0 3 x 104
2 <40 <40 <40 <40
Determined by plaque titration of 10% brain or liver homogeniate. The limit of sensitivity of the plaque titration assay was 40. No virus was detected in variant
strain-infected tissues later than day 7.
Data from Knobler et al. (15).
glycoprotein of MHV-4 plays a role in determining viral
pathogenicity in vitro (6, 26) and in vivo (2, 3. 29). We used
MAbs against two distinct topographical sites on MHV-4 E2
to select variant virus strains containing a mutation in E2,
and we studied the effect of such mutations on virulence. We
calculated that these variants arose in the population at a
mutation frequency of approximately iO4 to 1046, a value
which agrees with the predicted mutation frequency for
single-stranded RNA viruses of 10-4 to 10-5 (17, 21), making
it improbable that the variants we derived contained addi-
tional non-E2 mutations which could have affected pathoge-
nicity.
Characterization of six variant virus strains representing
the two independent epitopes E2B and E2C (31) by neutral-
ization and antibody-binding assays demonstrated that se-
lection for MAb resistance at epitope E2B also resulted in
changes at epitope E2C. The reciprocal was also observed,
i.e., selection for resistance at E2C resulted in changes at
E2B. Additional binding studies showed that several MAbs
which recognize antigenic sites distinct from epitopes E2B
and E2C (8, 30) also failed to bind to the E2 variants we
selected, indicating that these epitopes were also altered.
This observation of simultaneous acquisition of resistance at
multiple epitopes can best be reconciled if a point mutation
has resulted in conformational changes in the E2 molecule.
The fact that topographically distinct epitopes are affected
suggests that these sites may be clustered. Previous studies
from our laboratory (31) showed that the MAbs we used to
select variants recognize conformational sites on E2. In
contrast to the relative ease with which we isolated mutants
affecting epitopes E2B and E2C, we were unable to select
mutants with MAb against the sequential epitope E2A (data
not shown). Confirmation of the location and nature of the
mutation(s) on E2 will require nucleotide sequence and
protein structural data which is not currently available.
Disease induced by the variant viruses was characterized
by moderate early inflammatory lesions in the brain and
spinal cord which subsided between 15 and 22 days, leaving
foci of demyelinated axons. As disease progressed, evidence
of remyelination and new demyelination was observed. At
the termination of the present observations 65 days postin-
fection, demyelination was extensive. A similar course of
primary demyelination was observed after infection with
MHV-4 ts8 (11); however, in that model, inflammation is not
a prominent feature of the disease. Koolen et al. (M. J. M.
Koolen. W. Wouda, J. Calafat, M. C. Horzinek, and
B. A. M. van der Zeijst, personal communication) reported
the isolation of a temperature-sensitive mutant, ts342, of the
hepato-neurovirulent MHV strain A59. Whereas wild-type
A59 virus-infected mice died of hepatitis, W342-infected
mice survived and developed chronic demyelinating disease
characterized by infection of oligodendrocytes and
astrocytes, accompanied by widespread inflammatory reac-
tions in the white matter. These investigators isolated three
independent revertants of ts342 with biological properties
indistinguishable from the wild-type A59 virus. Thus it
appears that attenuation in this case also results from a single
point mutation. The absence of encephalomyelitis after
variant virus infection is most probably attributable to a
change in viral tropism resulting in sparing of the neurons.
Under these conditions, the demyelinating potential of the
virus becomes the predominant pathologic feature. Such
altered cell tropism was already demonstrated for ts8, which
infects oligodendrocytes but not neurons (15). and studies
are being carried out to characterize the tropism of the
variants.
The fate of the virus postinfection remains to be deter-
mined. We were unable to reisolate infectious virus later
than 15 days postinfection, although a cytopathic effect
typical of MHV-4 was seen in cultures cocultivated with
brain cells taken 32 days postinfection. This may reflect
sequestration of the virus or deficiencies in the methods
available for recovery. Nonetheless, we demonstrated that
the virus reisolated at 15 days retained the variant pheno-
type. Observation of moderate inflammatory response in the
CNS suggests that the disease may have an immune-
mediated component. We are currently assaying tissues
taken through the course of infection for viral antigens and
RNA in an effort to define the fate of virus during the course
of infection.
Similar observations of site-specific alteration of
neurovirulence have been made in other virus infections.
Inoculation of newborn mice with reovirus type 3 results in
acute fatal encephalitis with virus replication occurring in
neurons in multiple regions of the cerebral cortex. Spriggs
and Fields (24) used neutralizing MAb against the hemagglu-
tinin molecule (r 1) to select variant viruses which were
attenuated with respect to neurovirulence and showed re-
duced replication in the brains of newborn mice. Infection by
these variants was regionally localized in the hippocampus
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(23) and failed to spread throughout the CNS. Reduced
neurovirulence was traced to altered tropism, resulting in
restricted growth in the CNS, and recent studies showed that
the site plays a role in binding to cellular receptors on
neurons (20).
Similar findings have been documented in rhabdoviruses
and bunyaviruses. Variants of rabies virus shown by se-
quencing to contain single point mutations in the G protein
are nonpathogenic in adult mice (7). Variants of La Crosse
virus (10) are reduced in their capacity to replicate in striated
muscle, resulting in decreased viremia and spread to the
CNS. In this case, the effect was systemic, because virus
inoculated i.c. was fully neurovirulent.
Although we have no definitive evidence for such a
mechanism in the MHV-4 system, the loss of ability of E2 to
interact with cellular receptors is an attractive hypothesis to
explain the loss of neurovirulence of the MHV-4 variants we
selected. Further studies of the nature of the alterations in
E2 and the tropism of the variants should enable us to assess
the role of E2 in virus tropism and pathogenicity.
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